FORMULATION AND IN VIVO EVALUATION OF ACYCLOVIR LOADED CHITOSAN NANOPARTICLES FOR OCULAR DELIVERY
Abstract
The present study was aimed to formulate and evaluate chitosan nanoparticles containing acyclovir as potential ophthalmic drug delivery system. The topical application of acyclovir as eye ointment remains a concern for effective management of various ocular viral diseases owing to poor ocular drug bioavailability. The acyclovir loaded chitosan nanoparticles were prepared by ionic gelation of chitosan. Differential scanning calorimetry and fourier transform infra red spectroscopy measurements were carried out on the prepared nanoparticles, pure acyclovir and chitosan polymer. Fifteen different formulations were prepared and evaluated for particle size, Zeta potential, scanning electron microscopy, entrapment and loading capacity and in-vitro drug release profile. All the prepared formulations resulted in nano size in 377.9 to 720.6 nm and displayed spherical shape with zeta potential of +33.2 to +42.8 mV. The encapsulation efficiency and loading capacity were 70.7% - 90.9% and 25% - 50.8% respectively. The acyclovir loaded chitosan nanoparticles displayed crystallinity than acyclovir. The in-vitro release profile of acyclovir from the nanoparticles showed a sustained release of the drug over a prolonged period of 24 hours and fit best with Higuchi model with zero order and non- Fickian diffusion was superior phenomenon. The in vivo results reveal that ocular viral infections can be inhibited by the nanoparticles more significantly than the drug in conventional dosage forms. No appreciable difference was observed during 90 days in which nanoparticles were stored at various temperatures. Thus the results suggest that acyclovir loaded chitosan nanoparticle suspension appears promising for effective management of ocular viral infections.
Keywords:
Acyclovir, Chitosan nanoparticles, Ocular delivery, Ionic gelation method.DOI
https://doi.org/10.25004/IJPSDR.2017.090304References
2. Farooq AV, Shukla D. Herpes simplex epithelial and stromal keratitis: an epidemiologic update. Survey of ophthalmology. 2012 Oct 31; 57(5):448-62.
3. Jabs DA. Acyclovir for recurrent herpes simplex virus ocular disease. N. Engl. J. Med. 1998; 339:300–306.
4. Ohashi Y. Treatment of herpetic keratitis with acyclovir: benefits and problems. Ophthalmologica. 1997;211(Suppl. 1):29-32.
5. Aylward GW, Claoue CM, Marsh RJ, Yasseem N. Influence of oral acyclovir on ocular complications of herpes zoster ophthalmicus. Eye. 1994 Jan 1;8(1):70-4.
6. Pavan-Langston D. Herpetic infections. In G. Smolin and R. A.Thoft (eds.), The Cornea, 3rd ed., Little Brown, Boston, Massachusetts. 1994; 183–214.
7. John G, Hopkins U and Baltimore H. Acyclovir. AIDS Info. 2005; (1)14- 15, Available from: URL: http://aidsinfo.nih.gov.
8. Taskintuna I, Banker AS, Flores-Aguilar M, Bergeron-Lynn G, Aldern KA, Hostetler KY, Freeman WR. Evaluation of a novel lipid prodrug for intraocular drug delivery: effect of acyclovir diphosphate dimyristoylglycerol in a rabbit model with herpes simplex virus-1 retinitis. Retina (Philadelphia, Pa.). 1996 Dec;17(1):57-64.
9. Genta I, Conti B, Perugini P, Pavanetto F, Spadaro A, Puglisi G. Bioadhesive microspheres for ophthalmic administration of acyclovir. Journal of pharmacy and pharmacology. 1997 Aug 1;49(8):737-42.
10. Calvo P, Alonso MJ, Vila‐Jato JL, Robinson JR. Improved ocular bioavailability of indomethacin by novel ocular drug carriers. Journal of Pharmacy and Pharmacology. 1996 Nov 1;48(11):1147-52.
11. De Campos AM, Sánchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. International journal of pharmaceutics. 2001 Aug 14;224(1):159-68.
12. Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharmaceutical research. 1994 Sep 1;11(9):1358-61.
13. Silverstein RM, Webster FX, Kiemle DJ, Bryce DL. Spectrometric identification of organic compounds. John wiley & sons; 2014 Sep 29.
14. Willard HH, Merritt L, Dean JA, Settle FA. Thermal Analysis in Instrumental Methods of Analysis. 6th edition; pp. 611-615.
15. Calvo P, Vila-Jato JL, Alonso MJ. Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. International Journal of Pharmaceutics. 1997 Jul 16;153(1):41-50.
16. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. International journal of pharmaceutics. 1983 May 1;15(1):25-35.
17. Higuchi T. Mechanism of sustained‐action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. Journal of pharmaceutical sciences. 1963 Dec 1;52(12):1145-9.
18. Castela N, Vermerie N, Chast F, Sauvageon-Martre HE, Denis J, Godard V, Goldschmidt P, Pouliquen Y. Ganciclovir ophthalmic gel in herpes simplex virus rabbit keratitis: intraocular penetration and efficacy. Journal of Ocular Pharmacology and Therapeutics. 1994;10(2):439-51.
19. Rockville MD. United States Pharmacopoeia XXV, NF. United States pharmacopoeial convention Inc. Maryland, USA.2004; 1426-30.
20. Fresta M, Panico A, Bucolo C, Giannavola C, Puglisi G. Characterization and In‐vivo Ocular Absorption of Liposome‐encapsulated Acyclovir. Journal of pharmacy and pharmacology. 1999 May 1;51(5):565-76.
21. Charoo NA, Kohli KA, Ali A, Anwer A. Ophthalmic delivery of ciprofloxacin hydrochloride from different polymer formulations: In-vitro and in-vivo studies. Drug Dev Ind Pharm. 2003;29(2):215–221.
22. Fresta M, Fontana G, Bucolo C, Cavallaro G, Giammona G, Puglisi G. Ocular tolerability and in-vivo bioavailability of polyethyl- 2-cyanoacrylate nanosphere-encapsulated acyclovir. J Pharm Sci. 2001,90(3):288–297.
23. ICH Q1A (R2), Stability testing guidelines: Stability testing of new drug substances and products. The European agency for the evaluation of medicinal products. CPMP/ICH/2736/99.2003;4-20.
24. Alonso MJ, Sanchez. A. Biodegradable nanoparticles as new transmucosal drug carrier. Carrier Based Drug Delivery. 2004; 283-295.
25. Lehr CM, Bouwstra JA, Schacht EH, Junginger HE. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. International journal of Pharmaceutics. 1992 Jan 1;78(1-3):43-8.
26. Felt O, Buri P, Gurny R. Chitosan: a unique polysaccharide for drug delivery. Drug development and industrial pharmacy. 1998 Jan 1;24(11):979-93.
27. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharmaceutical research. 1996 Dec 1;13(12):1838-45.
28. Dredan J, Antal I, Racz I. Evaluation of mathematical models describing drug release from lipophilic matrices. Int J Pharm. 1996;145:61-64.
29. Peppas NA. Analysis of fickian and non-fickian drug release from polymers. Pharm Acta. 1985; 60:110-11.
30. Siepmann J, Peppas NA. Modelling of drug releases from delivery systems based on hydroxypropyl methyl cellulose (HPMC). Adv Drug Del Rev. 2001; 48:139-57.
31. Govender S, Pillay V, Chetty DJ, Essack SY, Dangor CM, Govender T. Optimization and characterization of bioadhesive controlled release of tetracycline microspheres. Int J Pharm. 2005;306:24-40.
32. Dhawan S, Singla AK. Nifedipine loaded chitosan microspheres prepared by emulsification phase separation. Biotechnic Histochem. 2003;78:243-254.
33. Gündüz K, Özdemir Ö. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren's syndrome. Acta ophthalmologica. 1994 Aug 1;72(4):438-42.
34. Felt O, Gurny R, Baeyens V. Delivery of antibiotics to the eye using a positively charged polysaccharide as vehicle. Aaps Pharmsci. 2001 Dec 1;3(4):87-93.
Published

